Get in touch

Contact

Contact Us

we can help you with your existing or future projects

While many of our collaborators are located widely across North America, for Texas-based companies we are conveniently located in Angleton, Texas, about 40 miles south of the Texas Medical Center. Our location makes us an ideal choice for early stage pre-clinical collaborators located in the southeast portion of Texas. We would be happy to discuss your research and technology efforts and invite you to visit our facility to learn more about us and our capabilities.

Testimonials

what our clients say about us

"A small company with high caliber people. This company helped me address critical questions posed by the FDA."
Ebrahim S. Delpassand, M.D.Chairman & Medical Director Excel Diagnostics
"IsoTherapeutics has proven to be a partner able to adapt quickly to FUJIFILM's changing needs. Within two weeks, they had documentation in place for the preparation of two new blood testing kits, and prepared GMP batches of each for our clinical sites."
Takeaki Suzuki, Ph.D.Associate Director, Drug Development, Head of Operations, FUJIFILM Pharmaceuticals USA, Inc.
"The combination of R&D, cGMP and small animal testing facilities makes IsoTherapeutics the ideal partner for our radiopharmaceutical programs - from initial development to commercialization. The skills that IsoTherapeutics have brought to our product development programs over the past decade have proven to be a major contribution to our success."
Nigel R. Stevenson, Ph.D. COO, Serene, LLC
Get In Touch

Hey, let's talk

©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals® and IsoTherapeutics™ names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics

Melbourne (Australia) – 9 April 2024. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the completion of the acquisition of IsoTherapeutics Group, LLC (IsoTherapeutics).

IsoTherapeutics is a privately held, commercial-stage company that provides radiochemistry and bioconjugation development and contract manufacturing services to numerous companies in the radiopharmaceutical industry, including Telix. The acquisition further enhances Telix’s in-house development capabilities and expands Telix’s United States (U.S.) manufacturing footprint with particular focus on bioconjugation and isotope processing.

Dr Christian Behrenbruch, Managing Director and Group CEO of Telix said, “The acquisition of IsoTherapeutics Group is a significant milestone in Telix’s continued focus on vertical integration of development, supply and manufacturing and is highly complementary to Optimal Tracers (Sacramento, California), ARTMS (Vancouver) and our extensive commercial manufacturing infrastructure in Belgium. In the IsoTherapeutics team, we have partnered with some of the leading experts in radiochemistry and I am excited at what we can achieve together going forward.”

Visit Telix